[1. Cancer Research UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics, Accessed: May, 2018.]Search in Google Scholar
[2. Ilic M, Ilic I. Cancer mortality in Serbia, 1991-2015: an age-period-cohort and joinpoint regression analysis. Cancer Commun (Lond). 2018 Apr 10;38(1):10.10.1186/s40880-018-0282-3]Search in Google Scholar
[3. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14-25.10.1093/jnci/djp440]Search in Google Scholar
[4. Vignot S, André T, Caux C, Bouleuc C, Evrard S, Gonçalves A, Lacroix M, Magné N, Massard C, Mazeron JJ, Orbach D, Rodrigues M, Thariat J, Wislez M, L’Allemain G, Bay JO. [Hot topics in 2017 in oncology and hematology. A selection by the editorial board of Bulletin du Cancer]. Bull Cancer. 2018;105(1):6-14.10.1016/j.bulcan.2017.11.006]Search in Google Scholar
[5. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22(4):263-302.10.2165/00002018-200022040-00002]Search in Google Scholar
[6. Albini A, Pannesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102:14–25.10.1093/jnci/djp440]Search in Google Scholar
[7. Brana I, Tabernero J. Cardiotoxicity. Ann Oncol. 2010;21:173–179.10.1093/annonc/mdq295]Search in Google Scholar
[8. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. JACC. 2010;55:213–220.10.1016/j.jacc.2009.03.095]Search in Google Scholar
[9. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracicline therapy. JAMA. 1991;266:1672–1677.10.1001/jama.1991.03470120074036]Search in Google Scholar
[10. Stevens PL, Lenihan DJ. Cardiotoxicity due to Chemotherapy: the Role of Biomarkers. Curr Cardiol Rep. 2015 Jul;17(7):603.10.1007/s11886-015-0603-y]Search in Google Scholar
[11. ltena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009;10:391–399.10.1016/S1470-2045(09)70042-7]Search in Google Scholar
[12. Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basicunder-lying mechanisms. Pharmacol Ther. 2018; S0163-7258(18)30072-X.10.1016/j.pharmthera.2018.04.009]Search in Google Scholar
[13. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Ver-rill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337.10.1186/1471-2407-10-337]Search in Google Scholar
[14. SNPC. European Medicine Agency. Available in: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000682/human_med_001047.jsp&mid=WC0b01ac058001d124]Search in Google Scholar
[15. Cvetkovic RS, Scott LJ. Dexrazoxane: A review of its use for cardioprotection during anthracycline chemo-therapy. Drugs. 2005;68:1005–1024.]Search in Google Scholar
[16. Csapo M, Lazar L. Chemotherapy-Induced Cardiotoxicity: Pathophysiology and Prevention. Clujul Medical. 2014;87(3):135-142.]Search in Google Scholar
[17. SNPC. Food and Drug Agency. Available in: https://www.fda.gov/Drugs; https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020212]Search in Google Scholar
[18. Boucek RJ, Jr, Steele A, Miracle A, Atkinson J. Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol. 2003;3:319–29.10.1385/CT:3:4:319]Search in Google Scholar
[19. Abd El-Aziz MA, Othman AI, Amer M, El-Missiry MA. Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol. 2001;21:469–73.10.1002/jat.78211746193]Search in Google Scholar
[20. Hiona A, Lee AS, Nagendran J, Xie X, Connolly AJ, Robbins RC, et al. Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J Thorac Cardiovasc Surg. 2011;142:396–403.10.1016/j.jtcvs.2010.07.097317351221094500]Search in Google Scholar
[21. Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res. 2009;60:373–81.10.1016/j.phrs.2009.05.00719467331]Search in Google Scholar
[22. Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (prevention of left ventricular dysfunction with enalapril and carvedilol in patients submitted to intensive chemotherapy for the treatment of malignant hemopathies). J Am Coll Cardiol 2013; 61: 2355–2362.10.1016/j.jacc.2013.02.07223583763]Search in Google Scholar
[23. Riad A, Bien S, Westermann D, Becher PM, Loya K, Landmesser U et al. Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res 2009; 69: 695–699.10.1158/0008-5472.CAN-08-307619147586]Search in Google Scholar
[24. Gnad R, Kaina B, Fritz G. Rho GTPases are involved in the regulation of NF-kappaB by genotoxic stress. Exp Cell Res 2001; 264: 244–249.10.1006/excr.2001.516511262181]Search in Google Scholar
[25. Huelsenbeck J, Henninger C, Schad A, Lackner KJ, Kaina B, Fritz G. Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity. Cell Death Dis 2011; 2: e190.10.1038/cddis.2011.65318141521833028]Search in Google Scholar
[26. Ramanjaneyulu SV, Trivedi PP, Kushwaha S, Vikram A, Jena GB. Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice. J Physiol Biochem 2013; 69: 513–525.10.1007/s13105-013-0240-0]Search in Google Scholar
[27. Payne DL, Nohria A. Prevention of Chemotherapy Induced Cardiomyopathy. Curr Heart Fail Rep. 2017;14(5):398-403.10.1007/s11897-017-0353-9]Search in Google Scholar
[28. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, Ergin A. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258-62.10.1016/j.jacc.2006.07.052]Search in Google Scholar
[29. Pimprapa V, Edward Y. Prevention of Anthracycline-Induced Cardiotoxicity: Challenges and Opportunities. Journal of the American College of Cardiology. 2014; 64(9): 938-945.10.1016/j.jacc.2014.06.1167]Search in Google Scholar
[30. Mônica Samuel Avila, Silvia Moreira Ayub-Ferreira, Mauro Rogerio de Barros Wanderley, Fatima das Dores Cruz, Sara Michelly Gonçalves Brandão, Vagner Oliveira Carvalho Rigaud, et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity Journal of the American College of Cardiology. 2018; 71 (20) 2281-2290.10.1016/j.jacc.2018.02.049]Search in Google Scholar
[31. Purva Sharma, Stephanie Hakimian, Juan Camacho and Robert Chait. Prevention of chemo-induced cardiotoxicity with beta-blockers. Journal of the American College of Cardiology, 2018;71(11); DOI: 10.1016/S0735-1097(18)32344-1.10.1016/S0735-1097(18)32344-1]Search in Google Scholar
[32. Escudier B, Alexandre JB, Leclercq B, Morin P, Guyot JM, Nitenberg G. Cardiotoxicitt du 5-fluorouracil. Caract Cristiques, mkanisme, conduite pratique. Presse Med 1986; 15:6-11.]Search in Google Scholar
[33. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–2247.10.1016/j.jacc.2009.02.05019520246]Search in Google Scholar
[34. Puel C, Mathey J, Agalias A, Kati-Coulibaly S, Mardon J, et al. Dose–response study of effect of oleuropein, an olive oil polyphenol, in an ovariectomy/inflammation experimental model of bone loss in the rat. Clin. Nutr 2006; 25, 859–868.10.1016/j.clnu.2006.03.00916740345]Search in Google Scholar
[35. Gülkaç MD, Akpinar G, Ustün H, Ozön Kanli A. Effects of vitamin A on doxorubicin-induced chromosomal aberrations in bone marrow cells of rats. Mutagenesis 2004; 19, 231–236.10.1093/mutage/geh02115123789]Search in Google Scholar
[36. Santos RV, Batista Jr, ML, Caperuto EC, Costa Rosa LF. Chronic supplementation of creatine and vitamins C and E increases survival and improves biochemical parameters after doxorubicin treatment in rats. Clin. Exp. Pharmacol. Physiol. 2007; 34:1294–1299.]Search in Google Scholar
[37. Conklin KA. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr. Cancer Ther 2005; 4:110–130.10.1177/153473540527619115911925]Search in Google Scholar
[38. Huertas JR, Battino M, Lenaz G, Mataix FJ. Changes in mitochondrial and microsomal rat liver coenzyme Q9 and Q10 content induced by dietary fat and endogenous lipid peroxidation. FEBS Lett. 1991; 287:89–92.10.1016/0014-5793(91)80022-U]Search in Google Scholar
[39. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch. Biochem. Biophys. 2009;486:95–102.]Search in Google Scholar
[40. Goulas V, Exarchou V, Troganis AN, Psomiadou E, Fotsis T, Briasoulis E, Gerothanassis IP. Phytochemicals in olive-leaf extracts and their antiproliferative activity against cancer and endothelial cells. Mol. Nutr. Food Res. 2009; 53, 600–608.]Search in Google Scholar
[41. Quiles JL, Huertas JR, Battino M, Mataix J, Ramírez-Tortosa MC. Antioxidant nutrients and adriamycin toxicity. Toxicology. 2002; 180:79–95.10.1016/S0300-483X(02)00383-9]Search in Google Scholar
[42. Mukherjee S, Banerjee SK, Maulik M, Dinda AK, Talwar KK, Maulik SK. Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression. BMC Pharmacol. 2003; 3:16–24.10.1186/1471-2210-3-1632440114687418]Search in Google Scholar
[43. Lim HA, Kim JH, Kim JH, Sung MK, Kim MK, Park, JH, Kim JS. Genistein induces glucose-regulated protein 78 in mammary tumor cells. J. Med. Food 2006; 9:28–32.]Search in Google Scholar
[44. Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJ. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr. Rev. 2008; 66:445–454.]Search in Google Scholar
[45. Bulucu F, Ocal R, Karadurmus N, Sahin M, Kenar L, Aydin A, et al. Effects of N-acetylcysteine, deferoxamine and selenium on doxorubicin-induced hepatotoxicity. Biol. Trace Elem. Res. 2009; 14:25-31.]Search in Google Scholar
[46. Bulucu F, Oktenli C, Kenar L, Ocal R, Koc B, Inal V, Yamanel L, Yaman H, Sanisoglu YS, Aydin A. Efficacy of deferoxamine, N-acetylcysteine and selenium treatments in rats with adriamycin-induced nephrotic syndrome. J. Nephrol. 2008; 21: 576–583.]Search in Google Scholar
[47. Jemai H, El Feki A, Sayadi S. Antidiabetic and antioxidant effects of hydroxytyrosol and oleuropein from olive leaves in alloxan-diabetic rats. J. Agric. Food Chem. 2009; 57:8798–8804.10.1021/jf901280r19725535]Search in Google Scholar
[48. Choi BH, Kim CG, Lim Y, Shin SY, Lee YH. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett. 2008; 259:111–118.10.1016/j.canlet.2007.10.00318006147]Search in Google Scholar
[49. Monstrey SJ, Mullick P, Narayanan K, et al. Hyperbaric oxygen therapy and free radical production: An experimental study in doxorubicin (Adriamycin) extravasation injuries. Ann Plast Surg 1997; 38:163-168.10.1097/00000637-199702000-000119043586]Search in Google Scholar
[50. Akta S, Toklu AS, Olgac V. Hyperbaric oxygen therapy in Adriamycin extravasation: An experimental animal study. Ann Plast Surg 2000; 45:167-171.10.1097/00000637-200045020-0001210949345]Search in Google Scholar
[51. Karagoz B, Suleymanoglu S, Uzun G, Bilgi O, Aydinoz S, Haholu A, Turken O,Onem Y, Kandemir EG. Hyper-baric oxygen therapy does not potentiatedoxorubicin-induced cardiotoxicity in rats. Basic Clin Pharmacol Toxicol. 2008;102(3):287-92.10.1111/j.1742-7843.2007.00196.x18248515]Search in Google Scholar
[52. Goolsby, Tiffany V. et al. Extravasation of Chemotherapeutic Agents: Prevention and TreatmentSeminars in Oncology. 2006; 33(1); 139-143.10.1053/j.seminoncol.2005.11.00716473651]Search in Google Scholar
[53. Newton RU, Galvão DA. Exercise in prevention and management of cancer. Curr Treat Options Oncol. 2008;9(2-3):135-46.10.1007/s11864-008-0065-118704691]Search in Google Scholar
[54. Rajarajeswaran P, Vishnupriya R. Exercise in cancer. Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology. 2009;30(2):61-70.10.4103/0971-5851.60050288588220596305]Search in Google Scholar
[55. Payne DL, Nohria A. Prevention of Chemotherapy Induced Cardiomyopathy. Curr Heart Fail Rep. 2017;14(5):398-403.10.1007/s11897-017-0353-928779279]Search in Google Scholar
[56. Jones LW, Habel LA, Weltzien E, Castillo A, Gupta D, Kroenke CH, et al. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. Jpn J Clin Oncol. 2016;34:2743–9.10.1200/JCO.2015.65.6603501974627217451]Search in Google Scholar
[57. Haykowsky MJ, Mackey JR, Thompson RB, Jones LW, Paterson DI. Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training. Clin Cancer Res. 2009; 15:4963–7.10.1158/1078-0432.CCR-09-062819622583]Search in Google Scholar
[58. Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. American Journal of Physiology - Heart and Circula-tory Physiology. 2015; 309(9):H1453-H1467.10.1152/ajpheart.00554.2015466697426386112]Search in Google Scholar
[59. Fandeev OA, Vasechkin SS, Alekhin MN, Odintsov SV, Kallistov VE, Sidorenko BA. Clinical value of antracycline toxicity: modern approaches to diagnosis,prevention, and treatment. Kardiologiia. 2011; 51(7):40-6.]Search in Google Scholar